Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atrovent® Inhalation Solution | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in total severity of the clinical picture rated on a 4-point scale | Up to 4 weeks after first study drug administration | |
| Investigator assessment of improvement of the clinical picture of the course on a 6-point symptoms profile | up to 4 weeks after first study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of efficacy by investigator on a 4-point scale | Up to 4 weeks after first study drug administration | |
| Assessment of efficacy by patient on a 4-point scale | Up to 4 weeks after first study drug administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with chronic obstructive airways disease recruited at pneumologists and internists
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
| Assessment of tolerability by investigator on a 4-point scale | Up to 4 weeks after first study drug administration |
| Assessment of tolerability by patient on a 4-point scale | Up to 4 weeks after first study drug administration |
| Number of patients with adverse drug reactions | Up to 4 weeks after first study drug administration |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |